11/20
06:35 am
roiv
Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]
Low
Report
Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]
11/16
01:10 am
roiv
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at
Wall Street Z
Medium
Report
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at
Wall Street Z
11/14
07:22 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
11/13
07:31 am
roiv
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]
Medium
Report
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]
11/11
03:35 pm
roiv
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a "buy" rating on the stock.
11/11
10:38 am
roiv
Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
Low
Report
Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
11/11
07:03 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/10
12:34 pm
roiv
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript [Seeking Alpha]
Low
Report
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript [Seeking Alpha]
11/10
08:05 am
roiv
Roivant Sciences GAAP EPS of -$0.17 beats by $0.16, revenue of $1.57M misses by $5.35M [Seeking Alpha]
Low
Report
Roivant Sciences GAAP EPS of -$0.17 beats by $0.16, revenue of $1.57M misses by $5.35M [Seeking Alpha]
11/10
07:00 am
roiv
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Low
Report
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
10/30
10:48 am
roiv
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at Citigroup Inc. from a "hold" rating to a "strong-buy" rating.
Low
Report
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at Citigroup Inc. from a "hold" rating to a "strong-buy" rating.
10/29
10:09 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/27
04:10 pm
roiv
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Low
Report
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
10/21
10:02 am
roiv
Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) [Yahoo! Finance]
Low
Report
Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) [Yahoo! Finance]
10/5
05:18 am
roiv
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades [Yahoo! Finance]
Low
Report
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades [Yahoo! Finance]
10/4
05:11 pm
roiv
Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints [Yahoo! Finance]
Low
Report
Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints [Yahoo! Finance]
10/3
04:38 pm
roiv
Roivant Sciences files shelf registration for potential securities offerings [Seeking Alpha]
Low
Report
Roivant Sciences files shelf registration for potential securities offerings [Seeking Alpha]
9/29
01:03 pm
roiv
Live From The 2025 Forbes Under 30 Summit [Forbes]
Low
Report
Live From The 2025 Forbes Under 30 Summit [Forbes]
9/26
08:10 am
roiv
Get Insider Access To The Business Playbooks Of Billionaires At The Forbes Under 30 Summit [Forbes]
Low
Report
Get Insider Access To The Business Playbooks Of Billionaires At The Forbes Under 30 Summit [Forbes]
9/23
08:08 pm
roiv
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice [Yahoo! Finance]
Low
Report
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice [Yahoo! Finance]
9/18
12:59 pm
roiv
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $20.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $20.00 to $24.00. They now have a "buy" rating on the stock.
9/18
10:20 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
9/18
10:10 am
roiv
Roivant Sciences (NASDAQ:ROIV) was given a new $20.00 price target on by analysts at Jefferies Financial Group Inc..
Low
Report
Roivant Sciences (NASDAQ:ROIV) was given a new $20.00 price target on by analysts at Jefferies Financial Group Inc..
9/18
09:41 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Guggenheim from $15.00 to $21.00. They now have a "buy" rating on the stock.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Guggenheim from $15.00 to $21.00. They now have a "buy" rating on the stock.
9/18
09:41 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $20.00. They now have an "overweight" rating on the stock.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $20.00. They now have an "overweight" rating on the stock.